Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) Free cash flow
Gilead Sciences, Inc.'s free cash flow for fiscal 2025 was $9.5B, down 8.24% from $10.3B in fiscal 2024. Over the twelve months to 30 June 2026 it was $12.9B. Over the past ten years it has ranged from $7.4B (fiscal 2023) to $20.5B (fiscal 2015); the current reading is higher than 55% of that period. Gilead Sciences, Inc. ranks 7th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $9.5B | (8.24%) |
| FY2024 | $10.3B | 38.86% |
| FY2023 | $7.4B | (11.06%) |
| FY2022 | $8.3B | (22.78%) |
| FY2021 | $10.8B | 43.72% |
| FY2020 | $7.5B | (9.63%) |
| FY2019 | $8.3B | 11.28% |
| FY2018 | $7.5B | (33.89%) |
| FY2017 | $11.3B | (30.62%) |
| FY2016 | $16.3B | (20.50%) |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $3.4B | 41.45% |
| Mar 2026 | $2.4B | (22.26%) |
| Dec 2025 | $3.1B | (21.18%) |
| Sep 2025 | $4.0B | 450.14% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| MRK Merck & Co., Inc. compare | $16.1B |
| NVS Novartis AG compare | $15.2B |
| GILD Gilead Sciences, Inc. | $12.9B |
| BMY Bristol Myers Squibb Company compare | $11.4B |
| PFE Pfizer Inc. compare | $11.0B |
| AMGN Amgen Inc. compare | $10.2B |
| GSK GSK PLC Sponsored ADR compare | $7.6B |
| NVO Novo Nordisk A/S compare | $7.6B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement